Author Affiliations: Memorial Sloan-Kettering Cancer Center, New York, New York (Drs Bach and Azzoli); College of Medicine, SUNY Downstate Medical Center, Brooklyn, New York (Mr Mirkin); American Society of Clinical Oncology, Alexandria, Virginia (Mr Oliver); MD Anderson Cancer Center, Houston, Texas (Dr Berry); Emory University and American Cancer Society, Atlanta, Georgia (Dr Brawley); Colorado School of Public Health, Denver (Dr Byers); Washington University School of Medicine, St Louis, Missouri (Dr Colditz); Kaiser Permanente Southern California, Pasadena (Dr Gould); National Jewish Health Center, Denver, Colorado (Dr Jett); Baylor College of Medicine, Houston (Dr Sabichi); University of California, San Francisco (Dr Smith-Bindman); University of Washington, Seattle (Dr Wood); American Board of Internal Medicine, Philadelphia, Pennsylvania (Dr Qaseem); and Yale School of Medicine, New Haven, Connecticut (Dr Detterbeck).
Context Lung cancer is the leading cause of cancer death. Most patients are diagnosed with advanced disease, resulting in a very low 5-year survival. Screening may reduce the risk of death from lung cancer.
Objective To conduct a systematic review of the evidence regarding the benefits and harms of lung cancer screening using low-dose computed tomography (LDCT). A multisociety collaborative initiative (involving the American Cancer Society, American College of Chest Physicians, American Society of Clinical Oncology, and National Comprehensive Cancer Network) was undertaken to create the foundation for development of an evidence-based clinical guideline.
Data Sources MEDLINE (Ovid: January 1996 to April 2012), EMBASE (Ovid: January 1996 to April 2012), and the Cochrane Library (April 2012).
Study Selection Of 591 citations identified and reviewed, 8 randomized trials and 13 cohort studies of LDCT screening met criteria for inclusion. Primary outcomes were lung cancer mortality and all-cause mortality, and secondary outcomes included nodule detection, invasive procedures, follow-up tests, and smoking cessation.
Data Extraction Critical appraisal using predefined criteria was conducted on individual studies and the overall body of evidence. Differences in data extracted by reviewers were adjudicated by consensus.
Results Three randomized studies provided evidence on the effect of LDCT screening on lung cancer mortality, of which the National Lung Screening Trial was the most informative, demonstrating that among 53 454 participants enrolled, screening resulted in significantly fewer lung cancer deaths (356 vs 443 deaths; lung cancer−specific mortality, 247 vs 309 events per 100 000 person-years for LDCT and control groups, respectively; relative risk, 0.80; 95% CI, 0.73-0.93; absolute risk reduction, 0.33%; P = .004). The other 2 smaller studies showed no such benefit. In terms of potential harms of LDCT screening, across all trials and cohorts, approximately 20% of individuals in each round of screening had positive results requiring some degree of follow-up, while approximately 1% had lung cancer. There was marked heterogeneity in this finding and in the frequency of follow-up investigations, biopsies, and percentage of surgical procedures performed in patients with benign lesions. Major complications in those with benign conditions were rare.
Conclusion Low-dose computed tomography screening may benefit individuals at an increased risk for lung cancer, but uncertainty exists about the potential harms of screening and the generalizability of results.
Bach PB, Mirkin JN, Oliver TK, et al. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review. JAMA. 2012;307(22):2418–2429. doi:10.1001/jama.2012.5521
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: